OS Therapies Inc 8-K

What Happened

• On March 31, 2026, OS Therapies Inc. (OSTX) filed a prospectus supplement to its Form S-3 (File No. 333-289443) that covers the resale from time to time of up to 10,529,417 shares of the company’s common stock by the selling stockholders referenced in the supplement. The Form S-3 was originally filed on August 8, 2025 and declared effective August 12, 2025.
• The company filed a Current Report on Form 8-K (also dated March 31, 2026) to attach the legal opinion of its counsel, Olshan Frome Wolosky LLP, regarding the legality of the shares (Exhibit 5.1). The counsel’s consent is included as Exhibit 23.1.

Key Details

• Date filed: March 31, 2026.
• Shares covered: up to 10,529,417 common shares for resale by selling stockholders.
• Registration vehicle: Prospectus Supplement to Form S-3 (File No. 333-289443), originally filed Aug 8, 2025 and effective Aug 12, 2025.
• Legal opinion: Olshan Frome Wolosky LLP provided an opinion on the legality of the shares (filed as Exhibit 5.1).

Why It Matters

• This filing registers existing shares for public resale by selling stockholders, which can increase share liquidity and potentially affect supply in the market when resales occur.
• The attached legal opinion is a routine but important part of registration that supports the legality of the resale offering.
• The filing does not announce a new issuance of shares or a capital raise by the company; it documents resale rights for existing holders. Investors should monitor any subsequent sales filings or broker-dealer notices for timing and volume of resales.